Physician profile
Charna Klein
NPI 1447331608
$2,351.07
in general payments reported to CMS, 2019-2025
20 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $102 · 2021: $702 · 2022: $507 · 2023: $462 · 2024: $229 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $838.02 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $335.93 | 2020-2022 | |
| Cti Biopharma Corp. | $269.38 | 2022-2023 | Vonjo |
| Seagen INC. | $256.34 | 2021-2023 | Adcetris |
| Sobi, INC | $228.86 | 2024-2025 | |
| Salvin Dental Specialties, INC. | $210.73 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $168.70 | 2021-2025 | Tagrisso, Enhertu |
| Gilead Sciences, INC. | $155.89 | 2022-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $148.40 | 2019-2022 | |
| Medtronic, INC. | $145.07 | 2023 | Micra |
| Janssen Biotech, INC. | $134.12 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Amgen INC. | $57.12 | 2019 | |
| Merck Sharp & Dohme LLC | $52.44 | 2019-2025 | Keytruda |
| Macrogenics, INC. | $48.35 | 2022 | |
| Abbvie INC. | $26.43 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.65 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.93 | 2021 | |
| Pfizer INC. | $19.76 | 2024 | |
| Taiho Oncology, INC. | $18.75 | 2022 | |
| Servier Pharmaceuticals LLC | $17.18 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $15.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charna Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.